Scope and Claims Analysis for US Drug Patent 12,576,080 (Varenicline Nasal Spray for Dry Eye): What the Claims Cover, How Broad They Are, and the Likely US Patent Estate Risks
US Patent 12,576,080 is directed to a method of treating dry eye by local nasal administration of a varenicline liquid pharmaceutical formulation in a spray dosing range that is tightly defined by microgram-per-spray amount, mg/mL formulation concentration, and optional formulation attributes (notably no preservative and specific buffering systems/pH).
What does US 12,576,080 claim in one line?
A dry-eye treatment method using a varenicline nasal spray dosed 25–50 micrograms per spray twice daily with formulation 0.5–1 mg/mL, plus dependent claims that further narrow to no preservative and buffer/pH windows.
What is the independent claim 1 scope for US 12,576,080?
Claim 1 is the core enforceable anchor. It requires all of these elements:
- Indication: treating dry eye in a human
- Route/localization: locally administering a spray into a nostril
- Dosage frequency: twice daily
- Drug identity: varenicline
- Per-spray amount window: 25 micrograms to 50 micrograms of varenicline
- Formulation concentration window: about 0.5 mg/mL to about 1 mg/mL
- Form of formulation: a liquid pharmaceutical formulation (as defined by concentration and excipients in dependent claims)
Practical claim boundary for infringement design-arounds
Any competing method that changes at least one of the following can move outside claim 1:
- per-spray varenicline amount (leave 25–50 micrograms)
- dosing frequency (not “twice daily”)
- formulation concentration (leave 0.5–1 mg/mL)
- route/local administration “into a nostril” via spray (not nasal spray)
- indication (not dry eye)
Which dependent claims narrow claim 1, and by how much?
Dependent claims cluster into two types: formulation restrictions and spray regimen refinements, with some buffer/pH constraints and no preservative.
No-preservative narrowing
-
Claim 2: formulation does not include a preservative
This is a binary limitation. A product with any preservative likely falls outside these dependent claims.
-
Claims 10, 14, 25: each adds “does not include a preservative” in different base claim contexts.
Buffer and pH limitations
- Claims 3, 19, 21, 23, 20, 22, 24 (and related): formulation includes a phosphate buffer and pH around 7.0
- Claims 26–28: formulation uses a phosphate-citrate buffer with pH from around 5.0 to around 6.0
These create formulation-specific carve-ins:
- phosphate buffer + ~7.0 pH is one protected formulation family
- phosphate-citrate buffer + 5.0–6.0 pH is another
Spray amount and concentration interlocks beyond claim 1
Claims 4–13 provide a wider genus than claim 1 while still binding to microgram-per-spray and mg/mL concentration.
- Claim 4 (base for many dependents): spray into nostril; dry eye; varenicline; varenicline concentration 0.1–10 mg/mL; amount per spray 5–100 micrograms
- Claim 5: narrows concentration to 0.2–1 mg/mL
- Claim 6: narrows to 0.5–1 mg/mL (matches claim 1 concentration range)
- Claim 7: narrows per-spray amount to 5–50 micrograms
- Claims 8–9: combine narrower concentration 0.2–1 mg/mL and then 0.5–1 mg/mL
- Claims 11–13: specify per-spray 25–50 micrograms and then concentration 0.2–1 mg/mL and then 0.5–1 mg/mL (again converging on claim 1 core numbers)
Bilateral dosing language
- Claims 15–18 and 29: local administration is repeated in a second nostril.
This adds a route/dosing pattern requirement and can be a meaningful design-around if the method uses only one nostril.
How broad is claim 4 compared with claim 1?
Claim 4 is the broadest “genus” claim in the set you provided.
Claim 4 parameter ranges
- Concentration: 0.1 to 10 mg/mL
- Per-spray amount: 5 to 100 micrograms
- Route: spray into a nostril
- Indication: dry eye in a human
- Requires “one or more pharmaceutically acceptable inactive ingredients” (but does not impose preservative/no-preservative by default)
Comparison: claim 1 vs claim 4
- Claim 1 is tightly centered on:
- concentration: 0.5–1 mg/mL
- amount per spray: 25–50 micrograms
- dosing frequency: twice daily
- bilateral: not required in claim 1 (only in dependents)
- Claim 4 expands:
- concentration: 0.1–10 mg/mL (wider by 10x)
- amount: 5–100 micrograms (wider by 20x total window, though overlaps claim 1 range)
- does not require “twice daily” in the text you supplied (but it is likely implied only where specified by dependent claims; your claim text does not include a “twice daily” requirement in claim 4 itself)
Net effect: claim 1 is narrower; claim 4 is broader on the numeric windows and excipient inclusion, but still constrained by spray nasal administration of varenicline in defined per-dose concentration/amount envelopes.
What are the key “numerical tripwires” competitors must avoid?
The claim language defines three numerical variables that act as infringement tripwires:
- Per-spray dose (micrograms)
- claim 1: 25–50
- claim 4: 5–100
- dependent narrowings: 5–50, 25–50
- Formulation concentration (mg/mL)
- claim 1: 0.5–1
- claim 4: 0.1–10
- dependent narrowings: 0.2–1, 0.5–1
- pH/buffer system (dependent only)
- phosphate buffer + pH ~7.0
- phosphate-citrate buffer + pH 5.0–6.0
- Preservative presence (dependent only)
- “does not include a preservative” appears multiple times
A design-around that changes only one of these variables may still land within the broader dependent chain for claim 4, depending on what is changed.
What formulation elements are explicitly required?
Based on your claim set, the explicit required formulation elements are limited to dependent claims:
- Phosphate buffer with pH around 7.0 (multiple dependent claims: 3, 19–24, etc.)
- Phosphate-citrate buffer with pH 5.0–6.0 (claims 26–28)
- No preservative (claims 2, 10, 14, 25)
- Otherwise, claim 4 requires one or more pharmaceutically acceptable inactive ingredients but does not specify which excipients unless invoked by dependent claims.
This creates a likely prosecution and enforceability pattern: the independent and broadly parameterized claims (1 and 4) protect the dosing strategy, while buffer/pH and preservative restrictions protect specific formulation embodiments.
Does US 12,576,080 claim dosing frequency or bilateral administration broadly?
- Twice daily appears in claim 1 only (from your text).
So frequency is likely a key limitation for the tightest claim.
- Second nostril repetition is explicitly required only in later dependent claims (15–18 and 29).
So a competitor could potentially practice a single-nostril method and still fall under claim 1/4 unless the asserted claim is one of the “second nostril” dependents.
From an enforcement perspective, the plaintiff can select the claim that best matches the accused regimen.
What does “locally administering a spray into a nostril” exclude?
On its face, the claim language is confined to:
- nasal local administration
- spray dosage form
- administration “into a nostril” (not oral, not topical ocular, not intranasal nebulization if not a “spray” device, though “spray” can be litigated based on how the device dispenses)
The provided claim set does not mention ocular instillation, inhalation, or dry-powder systems, so those routes are not within the literal wording you supplied.
Patent landscape: what other claims/assets typically surround a US method patent like this?
You asked for “scope and claims and patent landscape,” including actionable landscape risks, but the prompt you provided contains only the claims. Without the patent publication record (family members, specification details, prosecution history, and other US patents in the same family), a complete, accurate landscape cannot be produced.
Accordingly, the analysis below focuses only on enforceable scope visible from the claim text itself and the direct infringement/validity variables it implies.
Key validity and enforceability vectors implicated by the claim structure
Even without other documents, the claim construction and likely litigation axes follow naturally from the numerics and formulation carve-outs.
1) “Spray amount” and concentration measurement
The claims require:
- micrograms per spray
- mg/mL concentration
Accused products often have variability across actuation counts, droplet retention, and dosing accuracy. The claim language will push the dispute toward:
- how “amount in the spray” is defined (nominal vs delivered)
- what counts as “concentration” (formulation concentration at manufacture vs during use)
- whether the device delivers the claimed amount into the nostril
2) Overlap between claim 1 and claim 4 genus
Because claim 4 sweeps from 0.1–10 mg/mL and 5–100 micrograms, it can catch dosing implementations that are outside claim 1’s tight window. In an assertion, a plaintiff will often plead both to avoid dependence on the exact narrowing.
3) Dependent “no preservative” and buffer/pH limitations
No-preservative and buffer/pH restrictions are formulation-critical. In litigation, defendants can:
- add a preservative (if method claim asserted is one of the “does not include a preservative” dependents)
- shift pH slightly outside “around 7.0” or outside “around 5.0 to around 6.0”
- switch buffer system away from phosphate or phosphate-citrate
But these are only effective if the asserted claims are those dependents.
How strong is the patent estate for varenicline nasal dry-eye therapy based only on these claims?
Strength hinges on whether the independent claim scope reads broadly enough to cover likely commercial dosing concepts:
- Prospective coverage: claim 4’s concentration and per-spray amount ranges are broad enough to encompass multiple formulation strengths and dosing systems.
- Cons: claim 1 adds “twice daily” and tighter ranges. Claim 4 does not require preservative absence or specific buffer, so it can still be asserted against many product forms.
- Enforcement leverage: dependent claims provide fallback positions (buffer/pH and no-preservative) to match specific accused formulations.
Based solely on the claim set, the patent is best characterized as protecting a dose-and-route method with numerical constraints plus specific formulation embodiments.
What generic entry risks exist for this specific method?
If a generic manufacturer seeks to enter a market using:
- varenicline nasal spray for dry eye
- dosing that falls within claim 4’s concentration and per-spray amount windows
then the method claims create a direct US non-infringement risk. Even if the generic reformulates excipients, claim 4 can still be implicated because it does not require absence of preservative or a specific buffer.
Risk reduces if a generic can move outside both:
- per-spray amount window (5–100 micrograms) or
- concentration window (0.1–10 mg/mL)
while also preserving the indication and route.
What would a likely “non-infringing” design look like?
In view of the literal numeric boundaries in your claim set, a plausible design-around would avoid at least one core requirement for the asserted claim path:
- use a different per-spray varenicline dose outside 5–100 micrograms (for claim 4) or outside 25–50 micrograms (for claim 1)
- use a concentration outside 0.1–10 mg/mL (for claim 4) or outside 0.5–1 mg/mL (for claim 1)
- change route away from “spray … into a nostril”
- if the claim asserted is a dependent “no preservative” claim, include a preservative
- if buffer/pH dependent claims are asserted, move away from phosphate ~7.0 or phosphate-citrate 5.0–6.0
Claim-by-claim scope matrix (from your provided list)
| Claim |
Core subject matter |
Key numeric limits |
Formulation limits |
Frequency / laterality |
| 1 |
dry eye; varenicline nasal spray method |
25–50 mcg/spray; 0.5–1 mg/mL |
n/a |
twice daily |
| 2 |
claim 1 + preservative exclusion |
same as claim 1 |
no preservative |
twice daily |
| 3 |
claim 1 + phosphate buffer |
same as claim 1 |
phosphate buffer; pH ~7.0 |
twice daily |
| 4 |
dry eye; varenicline nasal spray method (broad genus) |
5–100 mcg/spray; 0.1–10 mg/mL |
pharmaceutically acceptable inactives |
n/a in provided text |
| 5 |
claim 4 + concentration narrowing |
5–100 mcg/spray; 0.2–1 mg/mL |
n/a |
n/a |
| 6 |
claim 5 + tighter concentration |
5–100 mcg/spray; 0.5–1 mg/mL |
n/a |
n/a |
| 7 |
claim 4 + per-spray amount narrowing |
5–50 mcg/spray; 0.1–10 mg/mL |
n/a |
n/a |
| 8 |
claim 7 + concentration narrowing |
5–50 mcg/spray; 0.2–1 mg/mL |
n/a |
n/a |
| 9 |
claim 8 + tighter concentration |
5–50 mcg/spray; 0.5–1 mg/mL |
n/a |
n/a |
| 10 |
claim 9 + no preservative |
5–50 mcg/spray; 0.5–1 mg/mL |
no preservative |
n/a |
| 11 |
claim 4 + per-spray 25–50 |
25–50 mcg/spray; 0.1–10 mg/mL |
n/a |
n/a |
| 12 |
claim 11 + conc 0.2–1 |
25–50 mcg/spray; 0.2–1 mg/mL |
n/a |
n/a |
| 13 |
claim 12 + conc 0.5–1 |
25–50 mcg/spray; 0.5–1 mg/mL |
n/a |
n/a |
| 14 |
claim 13 + no preservative |
25–50 mcg/spray; 0.5–1 mg/mL |
no preservative |
n/a |
| 15 |
claim 4 + second nostril dosing |
5–100 mcg/spray; 0.1–10 mg/mL |
n/a |
repeated in 2nd nostril |
| 16 |
claim 8 + second nostril |
5–50 mcg/spray; 0.2–1 mg/mL |
n/a |
repeated in 2nd nostril |
| 17 |
claim 10 + second nostril |
5–50 mcg/spray; 0.5–1 mg/mL |
no preservative |
repeated in 2nd nostril |
| 18 |
claim 12 + second nostril |
25–50 mcg/spray; 0.2–1 mg/mL |
n/a |
repeated in 2nd nostril |
| 19 |
claim 4 + phosphate buffer |
5–100 mcg/spray; 0.1–10 mg/mL |
phosphate buffer; pH ~7.0 |
n/a |
| 20 |
claim 19 + pH around 7.0 |
same as 19 |
phosphate buffer; pH ~7.0 |
n/a |
| 21 |
claim 10? (as stated) + phosphate buffer |
as incorporated |
phosphate buffer |
n/a |
| 22 |
claim 21 + pH around 7.0 |
as incorporated |
phosphate buffer; pH ~7.0 |
n/a |
| 23 |
claim 13 + phosphate buffer |
25–50 mcg/spray; 0.5–1 mg/mL |
phosphate buffer |
n/a |
| 24 |
claim 23 + pH around 7.0 |
25–50 mcg/spray; 0.5–1 mg/mL |
phosphate buffer; pH ~7.0 |
n/a |
| 25 |
claim 24 + no preservative |
25–50 mcg/spray; 0.5–1 mg/mL |
no preservative |
n/a |
| 26 |
claim 4 + phosphate-citrate buffer |
5–100 mcg/spray; 0.1–10 mg/mL |
phosphate-citrate; pH 5.0–6.0 |
n/a |
| 27 |
claim 10 + phosphate-citrate + pH |
as incorporated |
phosphate-citrate; pH 5.0–6.0 |
n/a |
| 28 |
claim 14 + phosphate-citrate + pH |
as incorporated |
phosphate-citrate; pH 5.0–6.0 |
n/a |
| 29 |
claim 14 + second nostril |
as incorporated |
no preservative |
repeated in 2nd nostril |
Key Takeaways
- US 12,576,080 is a dosing-and-route method patent: dry eye treatment via varenicline nasal spray with defined microgram-per-spray and mg/mL concentration windows.
- Claim 4 is the broadest enforcement surface: 0.1–10 mg/mL and 5–100 micrograms per spray for nasal administration in a dry-eye method.
- Claim 1 is the tight “twice daily” anchor: 25–50 micrograms per spray with 0.5–1 mg/mL, dosed twice daily.
- Formulation escape is possible only if the asserted claim is a dependent formulation-limited claim:
- preservative presence can defeat “no preservative” dependents
- buffer/pH shifts can defeat phosphate ~7.0 or phosphate-citrate 5.0–6.0 dependents
- For generic and reformulation strategies, avoid falling into claim 4’s concentration and per-spray windows; excipient-only changes may not be enough.
FAQs
-
Can a varenicline nasal spray be outside the patent if it uses the same dose but a different buffering system?
If the asserted claim is limited to phosphate/pH or phosphate-citrate/pH, buffer changes can matter; claim 4 does not require buffer/pH.
-
Does the patent cover preservative-containing formulations?
Only where a “no preservative” dependent claim is asserted. Claim 4 by itself does not require absence of preservative in your provided text.
-
What is the lowest-risk design-around target in the claim set?
The most direct is moving the method outside claim 4’s 5–100 micrograms per spray and 0.1–10 mg/mL ranges, rather than relying on excipient changes.
-
Is bilateral (second nostril) administration required for every claim?
No. “Second nostril” appears in specific dependent claims. The broadest claims do not include that limitation in the text provided.
-
Does the patent require a specific device delivering “spray” drops?
The claims require “spray” into a nostril. The practical risk depends on how the dispensing device is characterized in litigation and whether delivery qualifies as “spray” and “into a nostril.”
References
- US Patent 12,576,080 (claims as provided by the user).
